These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 37609458)

  • 41. Changes in symptoms of anhedonia in adults with major depressive or bipolar disorder receiving IV ketamine: Results from the Canadian Rapid Treatment Center of Excellence.
    Rodrigues NB; McIntyre RS; Lipsitz O; Cha DS; Lee Y; Gill H; Majeed A; Phan L; Nasri F; Ho R; Lin K; Subramaniapillai M; Kratiuk K; Mansur RB; Rosenblat JD
    J Affect Disord; 2020 Nov; 276():570-575. PubMed ID: 32871688
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical, behavioral, and neural measures of reward processing correlate with escitalopram response in depression: a Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report.
    Dunlop K; Rizvi SJ; Kennedy SH; Hassel S; Strother SC; Harris JK; Zamyadi M; Arnott SR; Davis AD; Mansouri F; Schulze L; Ceniti AK; Lam RW; Milev R; Rotzinger S; Foster JA; Frey BN; Parikh SV; Soares CN; Uher R; Turecki G; MacQueen GM; Downar J
    Neuropsychopharmacology; 2020 Jul; 45(8):1390-1397. PubMed ID: 32349119
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating κ-opioid antagonism as a treatment for anhedonia.
    Krystal AD; Pizzagalli DA; Smoski M; Mathew SJ; Nurnberger J; Lisanby SH; Iosifescu D; Murrough JW; Yang H; Weiner RD; Calabrese JR; Sanacora G; Hermes G; Keefe RSE; Song A; Goodman W; Szabo ST; Whitton AE; Gao K; Potter WZ
    Nat Med; 2020 May; 26(5):760-768. PubMed ID: 32231295
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Diagnostic and dimensional evaluation of implicit reward learning in social anxiety disorder and major depression.
    Reilly EE; Whitton AE; Pizzagalli DA; Rutherford AV; Stein MB; Paulus MP; Taylor CT
    Depress Anxiety; 2020 Dec; 37(12):1221-1230. PubMed ID: 32906219
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Role of Dynorphin and the Kappa Opioid Receptor in Schizophrenia and Major Depressive Disorder: A Translational Approach.
    Clark SD
    Handb Exp Pharmacol; 2022; 271():525-546. PubMed ID: 33459877
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Reward processing in major depressive disorder and prediction of treatment response - Neuropharm study.
    Brandt IM; Köhler-Forsberg K; Ganz M; Ozenne B; Jorgensen MB; Poulsen A; Knudsen GM; Frokjaer VG; Fisher PM
    Eur Neuropsychopharmacol; 2021 Mar; 44():23-33. PubMed ID: 33455816
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review.
    Iadarola ND; Niciu MJ; Richards EM; Vande Voort JL; Ballard ED; Lundin NB; Nugent AC; Machado-Vieira R; Zarate CA
    Ther Adv Chronic Dis; 2015 May; 6(3):97-114. PubMed ID: 25954495
    [TBL] [Abstract][Full Text] [Related]  

  • 48. New generation antidepressants for depression in children and adolescents: a network meta-analysis.
    Hetrick SE; McKenzie JE; Bailey AP; Sharma V; Moller CI; Badcock PB; Cox GR; Merry SN; Meader N
    Cochrane Database Syst Rev; 2021 May; 5(5):CD013674. PubMed ID: 34029378
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pretreatment brain connectivity during positive emotion upregulation predicts decreased anhedonia following behavioral activation therapy for depression.
    Walsh EC; Eisenlohr-Moul TA; Minkel J; Bizzell J; Petty C; Crowther A; Carl H; Smoski MJ; Dichter GS
    J Affect Disord; 2019 Jan; 243():188-192. PubMed ID: 30245249
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Novel Pathways in the Treatment of Major Depression: Focus on the Glutamatergic System.
    Tomasetti C; Montemitro C; Fiengo ALC; Santone C; Orsolini L; Valchera A; Carano A; Pompili M; Serafini G; Perna G; Vellante F; Martinotti G; Giannantonio MD; Kim YK; Nicola MD; Bellomo A; Ventriglio A; Fornaro M; Berardis DD
    Curr Pharm Des; 2019; 25(4):381-387. PubMed ID: 30864501
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Anhedonia as a transdiagnostic symptom across psychological disorders: a network approach.
    Guineau MG; Ikani N; Rinck M; Collard RM; van Eijndhoven P; Tendolkar I; Schene AH; Becker ES; Vrijsen JN
    Psychol Med; 2023 Jul; 53(9):3908-3919. PubMed ID: 35348051
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Personalized Psychiatry and Depression: The Role of Sociodemographic and Clinical Variables.
    Perna G; Alciati A; Daccò S; Grassi M; Caldirola D
    Psychiatry Investig; 2020 Mar; 17(3):193-206. PubMed ID: 32160691
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Efficacy of psychedelics in psychiatry, a systematic review of the literature].
    Berkovitch L; Roméo B; Karila L; Gaillard R; Benyamina A
    Encephale; 2021 Aug; 47(4):376-387. PubMed ID: 33888297
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An update on NMDA antagonists in depression.
    Pochwat B; Nowak G; Szewczyk B
    Expert Rev Neurother; 2019 Nov; 19(11):1055-1067. PubMed ID: 31328587
    [No Abstract]   [Full Text] [Related]  

  • 55. Recent developments in the psychobiology and pharmacotherapy of depression: optimising existing treatments and novel approaches for the future.
    Farvolden P; Kennedy SH; Lam RW
    Expert Opin Investig Drugs; 2003 Jan; 12(1):65-86. PubMed ID: 12517255
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Considerations when selecting an antidepressant: a narrative review for primary care providers treating adults with depression.
    Montano CB; Jackson WC; Vanacore D; Weisler R
    Postgrad Med; 2023 Jun; 135(5):449-465. PubMed ID: 36912037
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A transdiagnostic meta-analysis of physical and social Anhedonia in major depressive disorder and schizophrenia spectrum disorders.
    Gandhi A; Mote J; Fulford D
    Psychiatry Res; 2022 Mar; 309():114379. PubMed ID: 35123252
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The kappa opioid receptor antagonist aticaprant reverses behavioral effects from unpredictable chronic mild stress in male mice.
    Jacobson ML; Wulf HA; Browne CA; Lucki I
    Psychopharmacology (Berl); 2020 Dec; 237(12):3715-3728. PubMed ID: 32894343
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Role of Ketamine in the Treatment of Psychiatric Disorders.
    Derakhshanian S; Zhou M; Rath A; Barlow R; Bertrand S; DeGraw C; Lee C; Hasoon J; Kaye AD
    Health Psychol Res; 2021; 9(1):25091. PubMed ID: 35106397
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Moderation of the Relationship Between Reward Expectancy and Prediction Error-Related Ventral Striatal Reactivity by Anhedonia in Unmedicated Major Depressive Disorder: Findings From the EMBARC Study.
    Greenberg T; Chase HW; Almeida JR; Stiffler R; Zevallos CR; Aslam HA; Deckersbach T; Weyandt S; Cooper C; Toups M; Carmody T; Kurian B; Peltier S; Adams P; McInnis MG; Oquendo MA; McGrath PJ; Fava M; Weissman M; Parsey R; Trivedi MH; Phillips ML
    Am J Psychiatry; 2015 Sep; 172(9):881-91. PubMed ID: 26183698
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.